Fiscal Year Ending March 2027 Q2 (Interim) Financial Summary [Japanese GAAP] (Consolidated)

Performance Overview

Consolidated results for the period were solid: net sales of 6,015 million yen (YoY +3.6%), operating income of 665 million yen (YoY +47.0%), ordinary income of 696 million yen (YoY +38.4%), and interim net income attributable to owners of parent of 583 million yen (YoY +25.6%). All three segments—Fine Chemicals, Flame Retardants, and Health Support—recorded higher sales and profits. By segment, Fine Chemicals had net sales of 2,940 million yen, Flame Retardants 2,357 million yen, and Health Support 717 million yen. Contributions came from ramping up mass production of new products and expanded overseas sales.

Full-year Outlook and Dividends

The consolidated full-year forecast was revised upward at the interim, with expected net sales of 12,500 million yen, operating income of 1,100 million yen, ordinary income of 1,250 million yen, and net income attributable to owners of parent of 950 million yen. Earnings per share are 115.23 yen. Dividends are 7.50 yen at the end of the second quarter and the full-year forecast is also 7.50 yen, totaling 15.00 yen per share.